Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$17.2 million.

  • Arcturus Therapeutics Holdings' Cash from Operations rose 2782.78% to -$17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.3 million, marking a year-over-year increase of 293.55%. This contributed to the annual value of -$59.7 million for FY2024, which is 23011.22% down from last year.
  • According to the latest figures from Q3 2025, Arcturus Therapeutics Holdings' Cash from Operations is -$17.2 million, which was up 2782.78% from -$5.8 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations registered a high of $160.3 million during Q4 2022, and its lowest value of -$49.0 million during Q1 2022.
  • Its 5-year average for Cash from Operations is -$12.6 million, with a median of -$30.1 million in 2024.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Cash from Operations tumbled by 54078.71% in 2021, and later soared by 47710.66% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash from Operations (Quarter) stood at -$42.5 million in 2021, then skyrocketed by 477.11% to $160.3 million in 2022, then crashed by 100.39% to -$629000.0 in 2023, then skyrocketed by 54.85% to -$284000.0 in 2024, then crashed by 5939.08% to -$17.2 million in 2025.
  • Its Cash from Operations stands at -$17.2 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$35.1 million for Q1 2025.